TP53 and hepatocellular carcinoma: Liver cancer is one of the most common malignant tumors worldwide and is associated with a high mortality rate.[1] Over the past decades, high‐throughput sequencing approaches have indicated that the most common types of mutations in liver cancer cells, including TRET and TP53 mutations, are undruggable.[2] Donafenib, a deuterated derivative of sorafenib, is an oral small molecule inhibitor of multiple receptor kinases, that is approved as the standard therapy for patients with advanced hepatocellular carcinoma (HCC).